
|Videos|May 5, 2021
- Modern Retina Summer 2021
- Volume 1
- Issue 1
Analyzing clinical results of dexamethasone implant effect on macular thickness
Author(s)David Hutton, Modern Retina Staff Reports
Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Advertisement
Daniel F. Kiernan, MD, a vitreoretinal surgeon at The Eye Associates, Sarasota, Florida, discusses the highlights of his 2021 ARVO virtual presentation on the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on optical coherence tomography (OCT) testing following vitreoretinal surgery.
Articles in this issue
almost 5 years ago
Pediatric ophthalmologists target inherited retinal diseasesalmost 5 years ago
Gaining a greater understanding of AMDalmost 5 years ago
VEGF and beyond: therapeutic targeting in retinal vascular disordersAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Geographic atrophy topography and quality of life: What the central 2.5-mm region reveals
2
Retina World Congress 2026: RVO as a window into systemic vascular health
3
No 'smoking gun' OCT biomarker found for DME outcomes: Insights from Protocol T
4
QA102 data suggest signal in intermediate dry AMD, but insignificant drusen volume change
5
























